Skip to search formSkip to main contentSkip to account menu

Velcade

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Orphan Nano drugs such as Rituxan, Revlimid, Soliris, Afinitor, Tasigna, Velcade, Avonex, Alimta, Yervoy, Sprycel, Rebif… 
2011
2011
( This article may be cited as Manickam Palaniappan, Shenoy Maithili, Woldie Indryas , Hari Pawan, Tuliani Tushar, Byrnes Timothy… 
Review
2011
Review
2011
In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma… 
2007
2007
A more widespread adoption of an approach taken by a new scheme in which payment for an anticancer drug is linked to treatment… 
Review
2007
Review
2007
  • 2007
  • Corpus ID: 26352273
We have further defined mechanism(s) by which OSU-03012 (OSU), a derivative of the COX2 inhibitor Celecoxib but lacking COX2… 
2005
2005
Background: PS 341 has demonstrated activity in multiple myeloma (MM), and PXD 101 is a new HDAC inhibitor, currently being… 
2004
2004
The first three clinical studies of bortezomib tested regimens of differing dose-intensities: once weekly for 4 wk on a 6 wk… 
2004
2004
7107 Background: Tax, a microtubule stabilizer, is active against NSCLC. Bortezomib (VELCADE), a reversible proteasome inhibitor… 
Review
2002
Review
2002
The proteasome is a multiprotease complex that degrades the majority of cellular proteins in a highly regulated manner. The…